FOLFOX6 + Bevacizumab

Indication

Chemotherapy for stage IV (metastatic) cancer

FOLFOX6 + Bevacizumab

• Leucovorin 400 mg/m2 iv over 2 hrs before 5-FU d1
• 5-FU 400 mg/m2 iv bolus d1 followed by 2400 mg/m2 iv over 46 hrs
• Oxaliplatin 100 mg/m2 iv d1
• Bevacizumab (Avastin) 5 mg/kg iv d1
• Q2w

Modified FOLFOX6 + Bevacizumab

• Leucovorin 400 mg/m2 iv over 2 hrs before 5-FU, d1
• 5-FU 400 mg/m2 iv bolus d1 followed by 2400 mg/m2 iv over 46 hrs
• Oxaliplatin 85 mg/m2 iv d1
• Bevacizumab (Avastin) 5 mg/kg iv d1
• Q2w

References

Hochster, HS et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with and without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE Studies. 2006 ASCO annual meeting. Abstract 3510